



SpePharm announces marketing authorizations of Loramyc® in the UK, in Denmark and in Belgium.

Amsterdam, The Netherlands, 16 February 2008 – SpePharm Holding, B.V., the pan-European specialty pharmaceutical company, announces the marketing authorizations of Loramyc in the United Kingdom, in Denmark and in Belgium.

According to the terms of the agreement signed in March 2007 with BioAlliance Pharma SA which developed and filed the product, SpeBio a 50/50 joint venture of SpePharm and BioAlliance Pharma will commercialize Loramyc® in the European markets – with the exception of France where it is already commercialized by BioAlliance Pharma.

Loramyc® 50 mg, a muco-adhesive buccal tablet provides an innovative delivery system of muconazole and is indicated for the treatment of oropharyngeal candidiases (OPC) in immuno-compromised patients.

Since the end of 2007, Spepharm has expanded its commercial organization to the main European markets, creating 4 subsidiaries in the UK, Germany, Italy and the Nordic countries (Denmark) to launch its first product.

“The granting of marketing authorizations to Loramyc® in the UK and in Denmark in January 2008, followed by Belgium in February 2008 are excellent news, commented Jean-François Labbé, CEO of SpePharm. We are expecting approvals in the other European countries involved in the Mutual Recognition Procedure. SpePharm commercial organization is rapidly expanding for the launches of Loramyc® in Europe”.

-end-

Media contact:

SpePharm

Jean-François LABBE

Managing Director

Tel: +33 (0) 1 56 60 58 60

jean-francois.labbe@spepharm.com

About SpePharm Holding, B.V.

SpePharm Holding, B.V. is a Dutch company with its registered office in Amsterdam, and its European operations based in Paris, France. SpePharm is an emerging pan-European specialty pharmaceutical company focused on acquiring, registering and marketing high medical value specialty medicines essentially for the hospital markets. Particular areas of therapeutic interest are oncology, haematology, critical and supportive care. SpePharm aims to be the preferred partner for pharmaceutical and biotechnology companies, especially those from outside of Europe, seeking to maximize product and commercial opportunities within Europe. SpePharm was founded in September 2006 by Jean-François Labbé together with leading life science investment firms TVM Capital and Signet Healthcare Partners (part of the Sanders Morris Harris Group). Jean-François Labbé is a former top executive at Hoechst Marion Roussel and Parke Davis with over 30 years of experience in international pharmaceutical management. SpePharm, through its founding management team, has a proven track record of successful development, registration, and/or commercialization of quality therapeutic products in supportive care, oncology and haematology, and in orphan diseases. SpePharm has already established a commercial presence in the UK, Germany, Italy and the Nordic countries ready to launch its first product during 2Q2008.

For more information about SpePharm, please visit the web site at www.spepharm.com